Behind the Screens with the Dallas Stars: How Content Creates A Rivalry

 

Although it is being phased out of the game as the years go on, fighting is still something hockey is known for. A well-timed bout can change the trajectory of a game, and it is a major moment for fans in the stands.

When fisticuffs are exchanged, the Dallas Stars entertainment team jumps at the chance to energize the crowd even further.

“Sports rivalries are harder to synthesize nowadays,” Senior Director of Game Presentation Jason Danby said. “I think sometimes to start a rivalry you have to throw the first punch.”

Spotlighting the passion of the players creates a bond between city and team, something that is important in a non-traditional market like Dallas. Making an adversary of the opposing team is also a deliberate tactic used by the entertainment group to build a ‘story within the story of the game’, according to Danby.

“Our entire production team enjoys creating an arsenal of jabs of the opponents,” Danby continued.

Despite its violent nature, hockey is still known as a sport of dignity and respect. The entertainment team in Dallas is careful to stay tongue-in-cheek throughout its production while still creating resentment towards the visiting skaters.

“It is all done from a good place, there’s nothing really mean-spirited about any of it. There’s a code of rules we follow, things we won’t say, places we won’t go,” Danby said.

Aside from scoring a goal, nothing gets a crowd on its feet at a hockey game quicker than a fight. Regardless of why fans rise though, the Stars’ entertainment team is prepared for the occasion with the right material at the right time.

Knowing the audience or customer is critical to any business and the Stars are well aware that fighting draws a certain amount of fans to the sport. Capitalizing on this energy, and creating that one moment that a first-time fan might remember is critical.

CATCH UP ON ALL OF THE EPISODES!

 

For the latest news, videos, and podcasts in the Sports & Entertainment Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!
Twitter – @SportsEntMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More